NeogenTC develops personalized tumor-infiltrating lymphocyte (TIL) therapies that utilize a patient's own immune cells to target and eliminate solid tumors, which are often resistant to conventional treatments. By culturing and reintroducing these immune cells, the company aims to enhance the specificity and efficacy of cancer treatment, addressing the challenge of effectively targeting diverse tumor antigens.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors are often resistant to conventional cancer treatments, posing a significant challenge in oncology. Current therapies may not effectively target the diverse range of antigens present on tumor cells, limiting treatment efficacy.
Solution
NeogenTC is developing personalized tumor-infiltrating lymphocyte (TIL) therapies designed to overcome the limitations of traditional cancer treatments. The company isolates TILs from a patient's own tumor tissue, expands these immune cells ex vivo, and then reintroduces them back into the patient to target and eliminate solid tumors. TILs can recognize a wide array of tumor-associated antigens, potentially leading to more effective and durable responses, especially in solid tumors. The company's TIL therapy aims to enhance the specificity and efficacy of cancer treatment by leveraging the patient's own immune system to combat the disease. NeogenTC's lead candidate, NEOG-100, is currently undergoing Phase 1 clinical trials for solid tumors, including breast and non-small cell lung cancer.
Target Audience
The primary target audience includes patients with solid tumors who have failed to respond to conventional treatments, as well as oncologists and medical centers specializing in cell-based immunotherapies.
Features
- Personalized TIL therapy using a patient's own immune cells
- Targets multiple tumor-associated antigens for enhanced efficacy
- Ex vivo expansion of TILs to generate a large population of tumor-reactive T cells
- NEOG-100: TIL cell therapy currently in Phase 1 clinical trials for solid tumors
- Potential for lower treatment costs compared to other cell therapies, such as CAR-T